Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. Two ...
Leerink Partnrs decreased their FY2025 earnings estimates for shares of Q32 Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now ...